Dyadic International shares surged over 21% on Tuesday after a Form 144 filing with the SEC on July 21, 2026, indicated that major shareholder Francisco Trust intends to sell more than 364,000 shares with an aggregate market value of approximately $539,000. As of July 6, 2026, Francisco Trust owned 4,328,045 shares, representing 11.58% of the company's outstanding common stock. Dyadic, which does business as Dyadic Applied BioSolutions, reported first-quarter 2026 revenue of $1.11 million, up from $393,572 a year earlier, driven by higher research and development revenue from the Proliant Agreement, increased grant funding from CEPI and the Gates Foundation, and a milestone payment under the Inzymes Agreement. The stock closed at $1.47, up 21.49%.
Palvella Therapeutics, Inc
Vor Biopharma IncDyadic International IncMajor shareholder Francisco Trust files to sell over 364,000 shares, but stock surges over 21% on the news.
